Episode Summary:

In this episode of the Pain Matters podcast, Host Sudheer Potru, DO, FASA, FASAM, and Co-Host Zafeer Baber, MD, offer a comprehensive discussion of the (relatively) new analgesic medication suzetrigine, emphasizing its impact on acute pain management. Approved by the FDA in January 2025, this oral medication offers promising alternatives for moderate-to-severe postoperative pain management. Delving into its mechanism, the conversation also covers the history of voltage-gated sodium (“NAV”) 1.8 channel research and its implications for patient care.

Throughout the episode, the hosts highlight suzetrigine’s unique mechanism of action, acting preferentially on the NAV 1.8 sodium channels located predominantly in the peripheral nervous system. The dialogue explores its advantages over traditional opioids, including reduced side effects such as sedation and constipation, making it an attractive option for enhancing postoperative recovery protocols like ERAS (Enhanced Recovery After Surgery). The conversation expands on the complexities of treating chronic pain and the potential for new Nav channel-targeting agents to revolutionize pain management employing targeted strategies.

Key Takeaways:

• Understanding Suzetragine: Suzetragine acts as a novel analgesic focusing on the NAV 1.8 sodium channels, offering reduced side effects compared to opioids, especially in postoperative settings.
• Mechanism and Discovery: The NAV 1.8 sodium channel, essential for pain signal propagation, was key to designing suzetrogine. Its function was inadvertently highlighted by genetic mutations found in individuals who couldn’t feel pain due to alterations in similar channels.
• Economic and Clinical Implications: Although suzetrogine is more expensive than traditional pain medications, its potential to reduce hospital-acquired complications could justify its cost in clinical settings.
• Future Prospects in Chronic Pain: Ongoing research into suzetrogine’s effectiveness for conditions like diabetic neuropathy could offer new opportunities in managing chronic pain.
• Broader Pharmacological Impacts: The development of NAV channel-targeted medications marks a significant milestone, signaling a shift towards more specialized pain management options.

*Views expressed by our hosts and guests are their own and do not necessarily reflect those of the hosts, their institutions, or the American Academy of Pain Medicine.